Bibliographic citations
Carranza, F., Paredes, S. (2017). Frecuencia de nefropatía diabética y factores asociados en pacientes con diabetes mellitus tipo 2 [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/621888
Carranza, F., Paredes, S. Frecuencia de nefropatía diabética y factores asociados en pacientes con diabetes mellitus tipo 2 [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2017. http://hdl.handle.net/10757/621888
@misc{renati/365543,
title = "Frecuencia de nefropatía diabética y factores asociados en pacientes con diabetes mellitus tipo 2",
author = "Paredes Yauri, Stephania Raquel",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2017"
}
Objectives: To determine the frequency and factors associated with diabetic nephropathy (DN) in endocrinologic outpatients with type 2 diabetes mellitus (T2DM) treated at the Edgardo Rebagliati Martins National Hospital between 2013-2014. Methods: We performed an analytical cross-sectional study. We reviewed clinical records to collect sociodemographic, clinical, and laboratorial variables. We obtained absolute and relative frequencies for qualitative variables and mean and standard deviation for quantitative variables. The bivariate analysis consisted in calculating crude (PR) and adjusted (aPR) prevalence ratios with their respective 95% confidence intervals (CI 95%), as well as chi-square and student’s t tests or U Mann Whitney test. We considered a significance level of 0.05. In the multivariate analysis, we used a generalized lineal model in which we used an epidemiological model with the variables related to DN and HbA1c. We use the program Stata v12.0. Results: We included 471 patients, mostly women (55.8%), with a mean age of 65 ± 11.4 years. Sixty-three percent were overweight or obese, 63.3% had arterial hypertension, 67.9% had an HbA1c greater or equal to 7%, and 58.4% had a complication due to DM2 without including DN. In addition, 81.3% of patients received oral antidiabetics therapy, and 48.6% used insulin. The prevalence of DN was 70.5%. The mean time between the diagnosis of T2DM and the diagnosis of DN was 14.2±10.1 years. The majority of patients (24.6%) had stage 1 chronic kidney disease. We found an association between DN and HbA1c equal to or higher than 7% (aPR: 1.19; CI 95%: 1.02-1.38: p: 0.024) and when they had more than 10 years of disease (aPR: 1.19; CI 95%: 1.03-1.38, p: 0.019). Conclusions: There is a high prevalence of DN, which is associated with poor glycemic control and longer disease duration. We must improve the control of patients with T2DM to prevent this complication from appearing.
This item is licensed under a Creative Commons License